TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04020562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild Resistive Expiratory Technique
Description: Mild Resistive Expiratory Technique (EMST150- five-week training protocol):~The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for five weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Breathing exercise: Deep breathing 10-15 repetitions twice a day. Assistive Coughing: 5-6 repetitions twice a day. ROM Exercises: Both active and passive limb ROM exercises 10-15 repetitions twice a day.~Sustained stretching: Both upper and lower limbs, 10 repetitions, held for 5 seconds, twice a day.~Splinting: According to patient's injury level Bracing: According to patient's injury level Functional Mobility: Mobilizing patient according to injury level Tilt table standing: 10-15 minutes once a day
Study: NCT04919317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Description: The experimental group received 4mg dexamethasone added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The control group received 1mL of 0.9% saline added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
Study: NCT04256343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium Oxide (D2O) Dose
Description: 1 of 3 differing deuterium oxide (D2O) doses will provided to each of the participants to be consumed daily to assess muscle protein synthesis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium Oxide (D2O) Dose
Description: 1 of 3 differing deuterium oxide (D2O) doses will provided to each of the participants to be consumed daily to assess muscle protein synthesis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium Oxide (D2O) Dose
Description: 1 of 3 differing deuterium oxide (D2O) doses will provided to each of the participants to be consumed daily to assess muscle protein synthesis.
Study: NCT02410629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music Glove
Description: Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hand Exercise Program
Description: Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
Study: NCT04188054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in sleeping position
Description: The new sleeping position requires you to re-position yourself in your bed when lying on your back so that your feet (and ankles) hang over the end of the mattress, i.e. off the end of the bed.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No change in sleeping position
Description: No change to your normal sleeping position
Study: NCT00937339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy
Description: Experimental group: One session per day, 3 sessions per week, for consecutive 8 weeks. The total duration of whole body vibration therapy will be about 10 minutes per session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise on the vibration platform with the device turned off
Description: Control group: One session per day, 3 sessions per week, for consecutive 8 weeks. The subjects will perform the same exercises on the vibration platform but no vibration will be applied.
Study: NCT02374983

Intervention type: OTHER
Intervention: Gamma knife radiosurgery re-planning with convolution algorithm
Description: The convolution algorithm, which uses the correlation between CT imaging density in Hounsfield units (HU) and electron density (ρe) of the tissues as input to predict dose distribution, can provide a better simulation of real delivered dose for GKR. By more accurately predicting the dose delivered, a better prediction of clinical effects can be made, increasing the potential clinical efficacy of treatment.~Convolution algorithm is now available in Leksell GammaPlan® 10 but there is not enough clinical data to support its use over TMR 10, which is the current clinical standard. Using convolution algorithm to recalculate the dose for the otherwise unaltered TMR 10 plan will provide valuable insight and understanding of the dosimetric differences between these planning algorithms.
Study: NCT01751282

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem Cell

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Stem Cell

Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: Stem Cell
Study: NCT02824445

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: individualized Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: individualized Transcranial Magnetic Stimulation
Study: NCT00607217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: Intramuscular injection of one 0.5-mL dose of influenza vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo for influenza vaccine
Description: Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: Intramuscular injection of one 0.5-mL dose of influenza vaccine
Study: NCT00087178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adriamycin
Description: adriamycin 60 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: epirubicin 100 mg/m2 IV every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
Study: NCT01186770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
Study: NCT02472899

Intervention type: OTHER
Intervention: Blood sample
Description: Non-interventional study based on blood samples taken at a single study visit

Intervention type: OTHER
Intervention: Blood sample
Description: Non-interventional study based on blood samples taken at a single study visit

Intervention type: OTHER
Intervention: Blood sample
Description: Non-interventional study based on blood samples taken at a single study visit
Study: NCT00572689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 10 microgram injected sub-cutaneously once

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Buccal/blood Sample Collection
Description: Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
Study: NCT00550199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589, Gemcitabine
Description: Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
Study: NCT05295381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cough machine (CM)
Description: Cough machine training is based on the cough assist machine Comfort Cough II (CC20), in which the inhalation and exhalation times are adjusted to 1-3 seconds, and the positive and negative pressure of the lower pressure 10-15 cmH2O is gradually increased to 30-40 cmH2O for the first time, 4-6 cycles/time, repeated 4-6 times, twice a day, five days a week, until the subject is weaned off the ventilator or transferred out of the ward. A modified Borg scale was used as an indicator of perceived dyspnea.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: abdominal weight training (AWT)
Description: abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: abdominal weight training (AWT)
Description: abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.
Study: NCT03217292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV patient-controlled analgesia (PCA) tramadol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV patient-controlled analgesia (PCA) tramadol
Study: NCT01631448

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin Glue
Description: The biological adhesive will be applied to the study group, with the spray technique in two atmospheres of pressure in a total amount of 10 ml.
Study: NCT03286764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peppermint Oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Distilled water spray as a placebo during Colonoscopy
Study: NCT00096213

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional surgery
Description: surgery
Study: NCT00003686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pilocarpine hydrochloride
Description: Pilocarpine 5 mg po qid x 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 5 mg po qid x 4 weeks
Study: NCT04174066

Intervention type: OTHER
Intervention: blood sample
Description: blood sample during planned in the follow-up of patients.

Intervention type: OTHER
Intervention: blood sample
Description: blood sample during planned in the follow-up of patients.

Intervention type: OTHER
Intervention: tissue sample
Description: tissue sample during planned in the follow-up of patients.

Intervention type: OTHER
Intervention: tissue sample
Description: tissue sample during planned in the follow-up of patients.

Intervention type: OTHER
Intervention: excreta
Description: urine sample during planned in the follow-up of patients.

Intervention type: OTHER
Intervention: excreta
Description: urine sample during planned in the follow-up of patients.
Study: NCT00562406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: laser photocoagulation to the retina at the area of edema

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Description: laser photocoagulation to the retina at the area of edema
Study: NCT04412889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA/CD19 dual-target CAR-T cell immunotherapy
Description: The intervention is a CAR-T cell immunotherapy targeted CD19 and BCMA. The dosage ranges from 2×10\^5 to 1×10\^6 CAR+T/Kg.
Study: NCT01665742

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene
Description: 1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks~AND~4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks~in conjunction with a weight management programme

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: 1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks~AND~4 x film-coated placebo tablets daily for 8 weeks~in conjunction with a weight management programme
Study: NCT04970940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days
Study: NCT03386526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1387 for Injection
Description: Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle
Study: NCT04534309

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Written Weight Loss Material
Description: Participants will receive written weight loss material by email.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight Loss App
Description: Participants will receive written weight loss material as well as instructions for using a free weight loss app on their phone or computer.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight Loss App
Description: Participants will receive written weight loss material as well as instructions for using a free weight loss app on their phone or computer.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Lifestyle Weight Loss Intervention (Coaching)
Description: Participants will receive weekly coaching phone calls to encourage regular dietary, exercise, and self-monitoring practices which encourage gradual, healthy weight loss.
Study: NCT05624853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin sustained release tablet
Description: pregabalin sustained release tablet 150mg qd for 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin immediate release capsule
Description: pregabalin immediate release capsule 75mg bid for 8weeks
Study: NCT05543304

Intervention type: DIAGNOSTIC_TEST
Intervention: radiological evaluation
Description: All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.

Intervention type: DIAGNOSTIC_TEST
Intervention: radiological evaluation
Description: All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.
Study: NCT02147626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based educational and motivational modules

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information and Screening Group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information and Screening Group
Study: NCT00952198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-403, glucokinase activator; oral
Description: multiple dose, escalating

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo
Study: NCT02785263

Intervention type: RADIATION
Group type: OTHER
Intervention: 2.15 gray and 1.8 gray. Max. 6 weeks.

Intervention type: RADIATION
Group type: OTHER
Intervention: 2.15 gray and 1.8 gray. Max. 6 weeks.

Intervention type: RADIATION
Group type: OTHER
Intervention: 2.15 gray and 1.8 gray. Max. 5 weeks.
Study: NCT01381497

Intervention type: DRUG
Intervention: Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)
Description: This is an observational study and patients were prescribed this medication before study start

Intervention type: DRUG
Intervention: Triptan monotherapy
Description: This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
Study: NCT02333253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrotide
Description: 0.25 cetrotide S.c was added on when leading follicle reach \>12 mm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrotide
Description: 0.25 cetrotide S.c was added on when leading follicle reach \>12 mm
Study: NCT03945513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPRI424 (dienogest/ethinylestradiol)
Description: One LPRI424 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
Study: NCT05287789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squatting position by footstool
Description: Before the study, the height of the toilet bowls in the patient rooms was measured as 42 cm. The stools to be used for the study are manufactured by ordering laminated with white medium density fiberboard and synthetic resin resistant to harsh chemicals. Stools are made of high quality non-slip materials for patient safety.~After the first postoperative ambulation, stable patients whose bowel movements resumed met their initial defecation needs with the squatting position created using a stool at the appropriate height on the water closet type toilet.~The patients used footstools throughout a week after discharge at home and in the hospital for defecation.
Study: NCT04369417

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response Resiliency Program for Siblings of Children with ASD
Description: Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program for Siblings of Children with ASD
Description: Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.
Study: NCT03889392

Intervention type: PROCEDURE
Intervention: Kidney transplantation and nephrectomy
Description: Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
Study: NCT05445089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvacrol
Description: Carvativir 6 mg/ml diluted for oral solution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Placebo
Study: NCT06727656

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nitrate + Hypoxia
Description: The combined effect of nitrate supplementation and hypoxia training on both performance and health at sea-level and altitude conditions.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Hypoxia
Description: The combined effect of placebo supplementation and hypoxia training on both performance and health at sea-level and altitude conditions.
Study: NCT00572832

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent human papillomavirus vaccine on-time administration
Description: The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given six months after dose 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent human papillomavirus vaccine delayed administration
Description: The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given 12 months after dose 1.
Study: NCT03786835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein supplementation and regular physical activity
Description: To determine if high protein diet and/or regular physical activity improves muscle and bone health

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein supplementation and regular physical activity
Description: To determine if high protein diet and/or regular physical activity improves muscle and bone health

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein supplementation and regular physical activity
Description: To determine if high protein diet and/or regular physical activity improves muscle and bone health